Lifesci Capital Raises Earnings Estimates for CG Oncology

CG Oncology, Inc. (NASDAQ:CGON) – Lifesci Capital lifted their FY2025 earnings per share estimates for CG Oncology in a report released on Wednesday, November 26th. Lifesci Capital analyst S. Slutsky now expects that the company will post earnings of ($2.11) per share for the year, up from their previous estimate of ($2.12). The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share. Lifesci Capital also issued estimates for CG Oncology’s Q4 2025 earnings at ($0.56) EPS and FY2026 earnings at ($3.18) EPS.

Other equities analysts also recently issued research reports about the company. Zacks Research upgraded CG Oncology from a “strong sell” rating to a “hold” rating in a research report on Monday, September 1st. Truist Financial set a $62.00 price target on CG Oncology in a report on Monday, November 24th. Morgan Stanley upped their price objective on shares of CG Oncology from $56.00 to $79.00 and gave the company an “overweight” rating in a report on Wednesday, September 17th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of CG Oncology in a research note on Monday, September 15th. Finally, Guggenheim started coverage on shares of CG Oncology in a report on Tuesday, October 7th. They set a “buy” rating and a $90.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $59.73.

CG Oncology Price Performance

CGON opened at $41.37 on Monday. The firm has a market capitalization of $3.34 billion, a price-to-earnings ratio of -20.28 and a beta of 1.29. The company’s 50 day simple moving average is $41.40 and its two-hundred day simple moving average is $32.42. CG Oncology has a 1-year low of $14.80 and a 1-year high of $45.94.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.57) earnings per share for the quarter, hitting the consensus estimate of ($0.57). CG Oncology had a negative net margin of 15,945.17% and a negative return on equity of 21.67%. The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.07 million.

Insider Transactions at CG Oncology

In other CG Oncology news, Director James Mulay sold 27,015 shares of the business’s stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $31.53, for a total transaction of $851,782.95. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Leonard E. Post sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 30th. The stock was sold at an average price of $40.09, for a total transaction of $200,450.00. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 75,359 shares of company stock worth $2,773,214.

Institutional Investors Weigh In On CG Oncology

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in CG Oncology by 11.4% in the third quarter. Vanguard Group Inc. now owns 6,577,281 shares of the company’s stock worth $264,933,000 after acquiring an additional 670,770 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of CG Oncology by 190.3% during the 3rd quarter. Wellington Management Group LLP now owns 5,512,779 shares of the company’s stock worth $222,055,000 after buying an additional 3,613,885 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in shares of CG Oncology by 15.0% in the 2nd quarter. Alliancebernstein L.P. now owns 2,164,214 shares of the company’s stock valued at $56,270,000 after buying an additional 281,637 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of CG Oncology by 409.9% in the 2nd quarter. Bank of America Corp DE now owns 1,736,769 shares of the company’s stock valued at $45,156,000 after buying an additional 1,396,170 shares in the last quarter. Finally, Franklin Resources Inc. grew its position in shares of CG Oncology by 12.7% in the 2nd quarter. Franklin Resources Inc. now owns 1,486,839 shares of the company’s stock valued at $38,658,000 after buying an additional 167,905 shares during the last quarter. Institutional investors and hedge funds own 26.56% of the company’s stock.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.